Eli Lilly and Company (Lilly) recently broke ground in Houston, Texas, one of ten US manufacturing sites — and the fifth location to produce domestic active pharmaceutical ingredients (API) — announced since 2020. As part of the company’s $50 billion push to reshore medicine production to meet growing demand at home and export American-made medicines to people around the world, the $6.5 billion Houston site will manufacture Foundayo (orforglipron), Lilly’s first synthetic oral GLP-1 medicine, along with other small-molecule medicines and advanced therapeutics.
David A. Ricks, Lilly Chair and CEO, commented: “We are thrilled to break ground on our latest ‘medicines made in America’ site in the great state of Texas. This $6.5B investment will help change the game for tens of millions of people suffering from overweight, obesity and its consequences like diabetes. We will make and ship Lilly’s latest products from Texas to people here at home and around the world.”
Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing Operations, added: “When you invest in a place like Houston, you invest in its people first. This facility will run on the talent of this community, powered by our relationship with San Jacinto College. We’re hiring across the greater Houston area to help residents build careers close to home. The facility itself is being built to the highest standards for safety, quality and responsible stewardship of the environment, and every one of these jobs helps bring innovative medicines to the patients counting on them.”
In addition to Foundayo, the Houston site will focus on advanced therapeutics that were not within reach even a few years ago. This will include oligonucleotides, a class of medicines that can work at the genetic level to switch off the production of specific proteins to treat disease closer to its source.
Producing this pipeline of medicines at scale requires manufacturing capacity built to match the pace of innovation. Lilly has announced ten US sites since 2020:
Five will produce API
Richmond, Virginia; Huntsville, Alabama; Houston, Texas; and two sites in Lebanon, Indiana – Lebanon API and Lilly Medicine Foundry, which will also focus on new production methods and making medicines for clinical trials
Four will make injectable medicines and manufacture devices
Research Triangle Park and Concord, North Carolina; Kenosha, Wisconsin; and Lehigh Valley, Pennsylvania
One will make genetic medicines, Lebanon Advanced Therapies
The Houston site will use state-of-the-art technologies, including machine learning, AI, digitally integrated systems, and advanced data analytics to drive right-first-time execution. Digital automation will be embedded throughout the site to streamline operations and ensure a reliable supply of safe, high-quality medicines.
Source: chemanager-online.com
The restructuring forms part of GSK’s “accelerating growth” strategy that was first announced in July. At the time, GSK CEO Luke Miels explained the pharma was seeking 1.9 billion pounds ($2.5 billion) in annual cost-savings by 2029 to fund the program.
Gilead Sciences and Vir Biotechnology have deepened their ties by inking a second deal, which will see the pair join forces to discover and engineer novel T-cell engager (TCE) therapies for solid tumours. Through this collaboration and licensing agreement, Gilead will hand over $90m upfront and up to $45m in potential near-term preclinical milestones.
AstraZeneca has inked a billion-dollar artificial intelligence (AI)-powered drug discovery partnership and licensing deal with insitro, to identify novel targets and therapies for a range of cardiometabolic diseases.
